Patents by Inventor David C. Myles

David C. Myles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7405208
    Abstract: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: July 29, 2008
    Assignee: Kosan Biosciences, Inc.
    Inventors: Daniel Santi, David C. Myles, Zong-Qiang Tian, C. Richard Hutchinson, Robert Johnson, Yi-Qing Zhou, Li Feng
  • Patent number: 7348436
    Abstract: Compounds and methods useful for the synthesis of (+)-discodermolide, a naturally occurring microtubule stabilizing agent useful as an anti-cancer agent.
    Type: Grant
    Filed: March 1, 2005
    Date of Patent: March 25, 2008
    Assignee: Kosan Biosciences Incorporated
    Inventors: David C. Myles, Simon James Shaw, Kurt F. Sundermann
  • Patent number: 7342124
    Abstract: Synthetic methods and intermediates useful in the preparation of lactone containing compounds such as discodermolide and compounds which mimic the chemical or biological activity of discodermolide are provided.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: March 11, 2008
    Assignees: The Trustees Of The University Of Pennsylvania, Kosan Biosciences, Inc.
    Inventors: David C. Myles, Mark Burlingame, Simon James Shaw, Kurt F. Sundermann, Brian Scott Freeze, IgnaciĆ³ Brouard Martin, Tomoyasu Hirose, Amos B. Smith, III
  • Patent number: 7247617
    Abstract: Sixteen membered macrolide anti-infective agents having a structure according to formula I where R1, R2, R3, R4, R5, and R6 are as defined herein, and related compounds are disclosed.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: July 24, 2007
    Assignee: Kosan Biosciences Incorporated
    Inventors: Hong Fu, Leonard Katz, David C. Myles
  • Patent number: 7241754
    Abstract: 2-Desmethyl ansamycins having a structure according to formula I, where R1, R2, R3, R4, R5 and R6 are as defined herein, and other 2-desmethyl ansamycins are useful as antiproliferative agents
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: July 10, 2007
    Assignee: Kosan Biosciences, Inc.
    Inventors: Zong-Qiang Tian, Robert McDaniel, David C. Myles, Kedar Gautam Patel, Misty Piagentini, Zhan Wang
  • Patent number: 7211568
    Abstract: 9-Desoxoerythromycin compounds of formula I wherein R1, R2, R3, R4, and R5 are as defined herein, are useful as prokinetic agents for treating disorders of gastric motility.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: May 1, 2007
    Assignee: Kosan Biosciences Incorporated
    Inventors: Yaoquan Liu, Christopher Carreras, David C. Myles
  • Patent number: 6939861
    Abstract: Various macrolide compounds such as those having the following formulas are provided where the variables have the values provided herein.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: September 6, 2005
    Assignee: Kosan Biosciences, Inc.
    Inventors: Gary Ashley, Simon James Shaw, Yandong Li, David C. Myles
  • Patent number: 6887993
    Abstract: Compounds having a structure according to formula I wherein the groups R1 and R4 are as defined in the specification, are useful as anti-proliferative agents.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: May 3, 2005
    Assignee: Kosan Biosciences, Inc.
    Inventors: Zong-Qiang Tian, Yaoquan Liu, David C. Myles, Zhan Wang
  • Patent number: 6875863
    Abstract: Compounds having a structure according to formula I wherein the groups R1 and R4 are as defined in the specification, are useful as anti-proliferative agents.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: April 5, 2005
    Assignee: Kosan Biosciences, Inc.
    Inventors: Zong-Qiang Tian, Yaoquan Liu, David C. Myles, Zhan Wang
  • Patent number: 6872715
    Abstract: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: March 29, 2005
    Assignee: Kosan Biosciences, Inc.
    Inventors: Daniel Santi, David C. Myles, Zong-Qiang Tian, C. Richard Hutchinson, Robert Johnson, Yi-Qing Zhou, Li Feng
  • Patent number: 6870049
    Abstract: Compounds having a structure according to formula I wherein the groups R1 and R4 are as defined in the specification, are useful as anti-proliferative agents.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: March 22, 2005
    Assignee: Kosan Biosciences, Inc.
    Inventors: Zong-Qiang Tian, Yaoquan Liu, David C. Myles, Zhan Wang
  • Patent number: 6855705
    Abstract: Compounds having a structure according to formula I wherein the groups R1 and R4 are as defined in the specification, are useful as anti-proliferative agents.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: February 15, 2005
    Assignee: Kosan Biosciences, Inc.
    Inventors: Zong-Qiang Tian, Yaoquan Liu, David C. Myles, Zhan Wang
  • Publication number: 20040018598
    Abstract: The present invention relates to compounds made by a subset of modules from one or more polyketide synthase (“PKS”) genes that are used as starting material in the chemical synthesis of novel molecules, particularly naturally occurring polyketides or derivatives thereof. The biologically derived intermediates (“bio-intermediates”) generally represent particularly difficult compounds to synthesize using traditional chemical approaches due to one or more stereocenters. In one aspect of the invention, an intermediate in the synthesis of epothilone is provided that feeds into the synthetic protocol of Danishefsky and co-workers. In another aspect of the invention, intermediates in the synthesis of discodermolide are provided that feed into the synthetic protocol of Smith and co-workers.
    Type: Application
    Filed: May 19, 2003
    Publication date: January 29, 2004
    Inventors: Daniel Santi, Gary Ashley, David C. Myles
  • Patent number: 6638927
    Abstract: Compounds of formula IA and IB are new where the variables R1 through R10 have the values set forth herein. Such compounds have use in treating diseases such as obesity and type II diabetes, and may be provided as pharmaceutical formulations in conjunction with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: October 28, 2003
    Assignee: Chiron Corporation
    Inventors: Paul A. Renhowe, Daniel Chu, Rustum S. Boyce, Zhi-Jie Ni, David Duhl, Effie Tozzo, Kirk Johnson, David C. Myles
  • Publication number: 20030114450
    Abstract: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.
    Type: Application
    Filed: August 5, 2002
    Publication date: June 19, 2003
    Inventors: Daniel Santi, David C. Myles, Zong-Qiang Tian, C. Richard Hutchinson, Robert Johnson, Yi-Qing Zhou, Li Feng
  • Publication number: 20030109682
    Abstract: Cytotoxin-targeting molecule conjugates comprising cytotoxin and an antibody, growth factor, or polysaccharide together with a pH-sensitive or redox potential-sensitive linker. Novel ansamitocins and recombinant genes and organisms that produce them. The use of the described conjugates in the treatment of cancer and other hyperproliferation diseases.
    Type: Application
    Filed: September 3, 2002
    Publication date: June 12, 2003
    Inventors: Daniel Santi, David C. Myles, Brian Metcalf, C. Richard Hutchinson, Gary Ashley
  • Publication number: 20020137939
    Abstract: Compounds of formula IA and IB are new 1
    Type: Application
    Filed: August 31, 2001
    Publication date: September 26, 2002
    Inventors: Paul A. Renhowe, Daniel Chu, Rustum S. Boyce, Zhi-Jie Ni, David Duhl, Effie Tozzo, Kirk Johnson, David C. Myles
  • Publication number: 20020128213
    Abstract: The present invention provides novel sixteen-membered macrolide compounds that are useful as anti-infective agents or as intermediates thereto. The present invention also provides methods for the preparation of these compounds, and methods and formulations for their use. In one aspect of the present invention, sixteen-membered macrolide possessing a side chain Z are provided where Z is aliphatic, aryl, alkylaryl, halide, ═NOR3, ═NNHR3, or —W—R3 where W is O, S, NC(═O)R4, NC(═O)OR4, NC(═O)NHR4 or NR4 where R3 and R4 are each independently hydrogen, aliphatic, aryl or alkylaryl. In another aspect of the present invention, bicyclic compounds are provided where one of the cyclic-components is a sixteen-membered macrolide and the other is a cyclic moiety whose cyclic structure is formed by between 3 and 10 atoms. In another aspect of the present invention, sixteen-membered macrolide compounds that bind to the domain II region of the 23S RNA are provided.
    Type: Application
    Filed: September 24, 2001
    Publication date: September 12, 2002
    Inventors: Leonard Katz, Gary Ashley, Mark A. Burlingame, Steven D. Dong, Hong Fu, Yong Li, David C. Myles
  • Publication number: 20020052028
    Abstract: The present invention relates to compounds made by a subset of modules from one or more polyketide synthase (“PKS”) genes that are used as starting material in the chemical synthesis of novel molecules, particularly naturally occurring polyketides or derivatives thereof. The biologically derived intermediates (“bio-intermediates”) generally represent particularly difficult compounds to synthesize using traditional chemical approaches due to one or more stereocenters. In one aspect of the invention, an intermediate in the synthesis of epothilone is provided that feeds into the synthetic protocol of Danishefsky and co-workers. In another aspect of the invention, intermediates in the synthesis of discodermolide are provided that feed into the synthetic protocol of Smith and co-workers.
    Type: Application
    Filed: August 9, 2001
    Publication date: May 2, 2002
    Inventors: Daniel Santi, Gary Ashley, David C. Myles